Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.

Roche (OTCQX:RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of a certain type of breast cancer with a PIK3CA mutation. The agency ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late last year, although full analysis of the OS has only been completed by ...

Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer. The Swiss ...